China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $1.77M invested in China SXT Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
31% less capital invested
Capital invested by funds: $2.58M → $1.77M (-$810K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $1.61M | – | – | – |
|
2
Renaissance Technologies
New York
| $146K | – | – | – |
|
|
BWA
3
Beam Wealth Advisors
Covington,
Louisiana
| $11K | – | – | – |
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $7K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$19K | – | – |
|
SXTC Hedge Fund Activity: Q4 2019 in Review
1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2019, worth a combined $1.77M — down 31% from $2.58M a quarter earlier.
Fund positioning in SXTC was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Susquehanna International Group, cutting an estimated $19K.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1.77M of China SXT Pharmaceuticals stock for Q4 2019, down 31% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q4 2019 and 0 closed out.
- The largest China SXT Pharmaceuticals seller in Q4 2019 was Susquehanna International Group, an estimated $19K sold.
Based on aggregated 13F filings for Q4 2019.